Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Missouri
Clinical trial register · United States · industry-sponsored

Clinical Trials in Missouri, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Missouri

1002 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Missouri
2027-03-10
Not yet open
NeuroGT
Phase 1/2
9
Missouri
2027-01-18
Recruiting
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
NCT07426419Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy
Affinia Therapeutics
Phase 1/2
22
Florida, Missouri, New York, Texas
2026-12
Recruiting
CellCentric Ltd.
Phase 3
450
California, Florida, Illinois, Maryland, Missouri, Montana, Pennsylvania, Texas
2026-11-18
Not yet open
Skin Cancer Detection in Primary Care With and Without DermaSensor
NCT07940036Skin Cancer, Basal Cell Cancer, Squamous Cell Carcinoma, Melanoma (Skin Cancer)
DermaSensor, Inc.
Not applicable
200
Missouri
2026-11-10
Recruiting
Shattuck Labs, Inc.
Phase 2
232
Arkansas, California, Florida, Kansas, Louisiana, Maryland, Massachusetts, Missouri
2026-11-09
Recruiting
Vaderis Therapeutics AG
Phase 3
240
Florida, Illinois, Indiana, Minnesota, Missouri, Utah
2026-11-02
Recruiting
Viking Therapeutics, Inc.
Phase 3
560
Arizona, California, Florida, Georgia, Indiana, Minnesota, Mississippi, Missouri
2026-11
Not yet open
Eli Lilly and Company
Phase 1
343
Florida, Kansas, Missouri, Texas, Utah
2026-11
Recruiting
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
NCT07684170Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors
Compass Therapeutics
Phase 2
58
Missouri, Washington
2026-11
Recruiting
Haya Therapeutics, Inc.
Phase 1
10
Massachusetts, Missouri, Ohio
2026-10-30
Recruiting
Kowa Research Institute, Inc.
Not applicable
340
California, Colorado, Georgia, Missouri, South Carolina, Texas, Virginia
2026-10-30
Recruiting
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-27
Recruiting
Tornier Perform™ Reversed Monopost Study
NCT07764614Non-inflammatory Degenerative Joint Disease, Rhematoid Arthritis, Correction of Functional Deformity, Fracture of the Humeral Head
Stryker Trauma and Extremities
Observational
150
California, Missouri, Ohio
2026-10-22
Recruiting
Eli Lilly and Company
Phase 1
617
Arkansas, California, Florida, Georgia, Missouri, New Jersey, Ohio, Texas
2026-10-22
Recruiting
Sagimet Biosciences Inc.
Phase 3
800
Arkansas, California, Florida, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-10-21
Recruiting
35Pharma Inc., a GSK company
Phase 1/2
126
Missouri, South Carolina, Texas
2026-10-21
Recruiting
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-10-19
Recruiting
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-16
Recruiting
ModernaTX, Inc.
Phase 4
200
Arizona, Kansas, Kentucky, Missouri
2026-10-15
Recruiting
Hoffmann-La Roche
Phase 1
180
Illinois, Missouri, Nebraska, Texas, Wisconsin
2026-10-13
Recruiting
Jazz Pharmaceuticals
Phase 2
50
California, Florida, Georgia, Kentucky, Missouri, South Carolina
2026-10-12
Recruiting
Biogen
Phase 1/2
69
Arizona, Missouri, Texas
2026-10-07
Recruiting
AiCuris Anti-infective Cures AG
Phase 2
24
Alabama, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2026-10-05
Recruiting
Janssen Research & Development, LLC
Phase 2
440
California, Massachusetts, Minnesota, Missouri, New York, Oklahoma, Texas
2026-10-05
Recruiting
Abiomed Inc.
Not applicable
250
California, Florida, Indiana, Minnesota, Missouri, New Jersey, New York, North Carolina
2026-10-02
Not yet open
NANOVAE to Treat Knee Osteoarthritis (KOA)
NCT06606561Knee Osteoarthritis
Nova Vita Laboratory
Phase 1/2
24
Missouri
2026-10-01
Not yet open
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
NCT07429838Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
eGenesis, INC
Phase 1/2
20
Missouri, Wisconsin
2026-10
Recruiting
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Emmecell
Phase 2
121
California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri
2026-10
Recruiting
Arrowhead Pharmaceuticals
Phase 3
10
Missouri
2026-10
Recruiting
Trevi Therapeutics
Phase 3
201
Alabama, Connecticut, Delaware, Florida, Maryland, Michigan, Missouri, North Carolina
2026-09-30
Recruiting
Pfizer
Phase 3
1,100
Illinois, Missouri, New York, Oklahoma, Pennsylvania, Texas
2026-09-30
Recruiting
Pfizer
Phase 3
660
Alabama, California, Florida, Indiana, Kentucky, Michigan, Mississippi, Missouri
2026-09-30
Recruiting
Evaluation of the F&P Mask, US, 2026
NCT07826429Chronic Respiratory Conditions, Obstructive Sleep Apnea (OSA)
Fisher and Paykel Healthcare
Not applicable
45
Missouri
2026-09-28
By invitation
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
NCT07607327AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
CareDx
Observational
400
California, Missouri
2026-09-24
Recruiting
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
Deepull Diagnostics S.L.
Observational
1,500
California, Florida, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2026-09-21
Not yet open
GlaxoSmithKline
Phase 1
25
California, Louisiana, Maryland, Missouri
2026-09-18
Recruiting
YolTech Therapeutics Co., Ltd
Phase 2
36
Alabama, Colorado, Missouri, Pennsylvania
2026-09-16
By invitation
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Cerus Corporation
Observational
320
Colorado, Florida, Maryland, Missouri
2026-09-15
Recruiting
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
NCT07766499Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Calixis Inc.
Phase 2
81
California, Florida, Georgia, Idaho, Louisiana, Maryland, Missouri, North Carolina
2026-09-15
Recruiting
ATR 1072 in Participants With PRKAG2 Syndrome
NCT07738107Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Atrium Therapeutics
Phase 1/2
37
Missouri, Texas
2026-09-14
Recruiting
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2026-09-10
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Merck Sharp & Dohme LLC
Phase 1
400
Florida, Maryland, Missouri, New Jersey, Ohio, Texas
2026-09-10
Recruiting
Bristol-Myers Squibb
Phase 3
850
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Minnesota, Missouri
2026-09-08
Recruiting
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Recruiting
GlaxoSmithKline
Phase 3
110
Florida, Kentucky, Missouri, Nevada, Oregon, South Carolina, Texas
2026-09-01
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Recruiting
Polyrizon Ltd.
Not applicable
120
Illinois, Missouri, New Jersey, Texas
2026-09-01
Recruiting
Pfizer
Phase 3
440
California, Colorado, District of Columbia, Georgia, Iowa, Louisiana, Maryland, Missouri
2026-08-31
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Palisade Bio
Phase 2
204
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2026-08-28
Recruiting
Oura Ring OA15 Validation
NCT07908199Healthy Adult, Sleep Apnea
Ouraring Inc.
Observational
60
Missouri
2026-08-28
Recruiting
Axsome Therapeutics, Inc.
Phase 3
705
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri
2026-08-27
Recruiting
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Missouri, Nebraska, North Dakota, Ohio
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Rademikibart IV for Acute Asthma and COPD Exacerbation
NCT07705737Asthma Acute, COPD Exacerbation Acute
Connect Biopharm LLC
Phase 2
40
Florida, Missouri
2026-08-21
Recruiting
Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System
NCT07455747Extracranial Carotid Artery Disease, TCAR, Transcarotid Artery Revascularization
Boston Scientific Corporation
Observational
5,000
Missouri
2026-08-19
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
California, Florida, Illinois, Missouri, New Jersey, Ohio, Texas, Virginia
2026-08-19
Recruiting
Macro Biologics, Inc.
Phase 1
44
California, Idaho, Maryland, Missouri, Ohio
2026-08-18
Recruiting
Alnylam Pharmaceuticals
Phase 2
58
Florida, Indiana, Kansas, Missouri, Ohio, Tennessee, Texas, Wisconsin
2026-08-17
Recruiting
Alkermes, Inc.
Phase 3
150
Arizona, Florida, Georgia, Kansas, Michigan, Minnesota, Missouri, New York
2026-08-13
Recruiting
Merck Sharp & Dohme LLC
Phase 1
280
California, Florida, Missouri, Nebraska, Ohio, Rhode Island, Texas
2026-08-12
Recruiting
Novo Nordisk A/S
Phase 3
450
Alabama, California, Florida, Hawaii, Kentucky, Missouri, Nevada, Oregon
2026-08-12
Recruiting
Genmab
Phase 3
960
Arkansas, California, Georgia, Indiana, Missouri, New York, Washington
2026-08-11
Not yet open
GlaxoSmithKline
Phase 3
1,860
Arkansas, California, Florida, Idaho, Illinois, Kentucky, Louisiana, Missouri
2026-08-11
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
OPKO Health, Inc.
Phase 2
40
Missouri, Ohio, Pennsylvania, South Carolina, Wisconsin
2026-08-05
Recruiting
BioNTech SE
Phase 1
126
Missouri, Tennessee, Texas
2026-08-04
Recruiting
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
NCT07824583Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
Varian, a Siemens Healthineers Company
Not applicable
20
Missouri, Ohio
2026-07-31
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 3
12
Alabama, California, Missouri, Texas, Washington
2026-07-31
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
Gilead Sciences
Phase 2/3
700
California, Connecticut, Florida, Georgia, Missouri, New Jersey, Texas, Washington
2026-07-29
Recruiting
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Eidos Therapeutics, a BridgeBio company
Phase 4
150
Maryland, Missouri, Pennsylvania
2026-07-28
Recruiting
Verastem, Inc.
Phase 2
150
Arizona, California, Florida, Indiana, Michigan, Missouri, New Jersey, New York
2026-07-28
Recruiting
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Missouri, Nebraska, New York, North Carolina
2026-07-27
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Atavistik Bio, Inc
Phase 1/2
100
Arizona, California, Georgia, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2026-07-27
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
GlaxoSmithKline
Phase 3
1,740
Arkansas, California, Florida, Maryland, Missouri, New York, North Carolina, Ohio
2026-07-22
Recruiting
GlaxoSmithKline
Phase 3
380
Arkansas, California, Florida, Missouri, New York, North Carolina, Ohio, Texas
2026-07-22
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Missouri, Texas
2026-07-20
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, Missouri, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Kinaset Therapeutics Inc
Phase 2
512
California, Florida, Illinois, Missouri, North Carolina, Pennsylvania, South Carolina, Texas
2026-07-16
Recruiting
Gilead Sciences
Phase 3
850
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2026-07-14
Active, closed
AstraZeneca
Phase 1/2
164
California, Illinois, Kansas, Missouri, Nebraska
2026-07-08
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
240
Alabama, Florida, Missouri, South Carolina, Tennessee, Texas
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey
2026-07-06
Not yet open
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Active, closed
Boehringer Ingelheim
Phase 2
345
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri, Ohio, Tennessee, Utah
2026-06-30
Recruiting
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Minnesota, Missouri
2026-06-29
Recruiting
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
NCT07721025Friedreich Ataxia, Cardiomyopathy, Secondary
Lexeo Therapeutics
Phase 2
26
Arkansas, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio
2026-06-25
Recruiting
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas, Washington
2026-06-23
By invitation
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 1
120
Missouri, Texas
2026-06-18
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Verastem, Inc.
Phase 2
185
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2026-06-16
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Active, closed
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction
NCT07657182Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury
Axogen Corporation
Phase 4
178
California, Florida, Indiana, Mississippi, Missouri, North Carolina
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Maryland, Michigan, Missouri, New Jersey
2026-06-11
Recruiting
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, North Carolina, Texas
2026-06-10
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Octapharma
Phase 3
360
Arizona, Missouri, Tennessee, Texas
2026-06-10
Active, closed
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Castle Biosciences Incorporated
Observational
450
Arizona, California, Florida, Maryland, Michigan, Missouri, Nevada, New Hampshire
2026-06-04
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Direct Biologics, LLC
Phase 2
36
Missouri
2026-06-01
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
NORM-HF Pivotal Study
NCT07574593Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
800
California, Florida, Louisiana, Massachusetts, Missouri, Nebraska, New York, North Carolina
2026-05-29
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
By invitation
Harrow Inc
Phase 3
250
Missouri
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-23
Recruiting
Claris Biotherapeutics, Inc.
Observational
500
California, Florida, Indiana, Kansas, Kentucky, Massachusetts, Minnesota, Missouri
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-22
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
Aspeya, Inc.
Phase 2
108
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Missouri, Nevada
2026-05-19
Recruiting
Gilead Sciences
Phase 2
170
Connecticut, Massachusetts, Missouri, South Dakota, Virginia
2026-05-19
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, California, Florida, Georgia, Illinois, Indiana, Missouri, Nebraska
2026-05-18
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Kansas, Maryland, Missouri, Nevada
2026-05-14
Recruiting
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
NCT07285005Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
Kaken Pharmaceutical
Phase 3
150
Missouri, North Carolina, South Carolina, Tennessee, Texas, West Virginia
2026-05-13
Recruiting
Denali Therapeutics Inc.
Phase 1/2
32
California, Missouri, North Carolina, Virginia
2026-05-12
Recruiting
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey
2026-05-11
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
390
Arkansas, California, Colorado, Delaware, Illinois, Indiana, Michigan, Missouri
2026-05-11
Recruiting
Abbott Nutrition
Observational
158
Missouri
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
AstraZeneca
Phase 2
104
Arizona, California, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma
2026-05-07
Recruiting
AstraZeneca
Phase 2
24
Missouri, Rhode Island, Tennessee
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
California, Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York
2026-05-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Florida, Illinois, Michigan, Missouri, Montana
2026-05-04
Recruiting
BeOne Medicines
Phase 2
30
Arizona, California, Florida, Missouri, Ohio
2026-04-30
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
CVRx, Inc.
Not applicable
2,500
Alabama, California, Florida, Illinois, Indiana, Massachusetts, Missouri, Nebraska
2026-04-24
Recruiting
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
NCT07429240Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.
Phase 1/2
18
Arkansas, Missouri
2026-04-24
Recruiting
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
NCT07303777Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Atom Therapeutics Co., Ltd
Phase 2
200
California, Missouri
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 3
20
California, Florida, Louisiana, Missouri, Ohio, Pennsylvania, Wisconsin
2026-04-21
Recruiting
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
By invitation
Ascension Health
Not applicable
2,200
Missouri
2026-04-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
Medtronic
Observational
970
Arizona, California, Missouri, Nebraska, Nevada, Pennsylvania, Texas
2026-04-17
By invitation
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
Hoffmann-La Roche
Phase 3
100
Colorado, Connecticut, Florida, Georgia, Missouri, New York, Ohio, Pennsylvania
2026-04-15
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
California, Georgia, Kentucky, Massachusetts, Michigan, Missouri, New Jersey, New York
2026-04-09
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Recruiting
Genmab
Phase 3
544
California, Connecticut, Florida, Maine, Maryland, Missouri, Nebraska, North Carolina
2026-04-03
Active, closed
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Recruiting
Neuspera Medical, Inc.
Observational
100
Missouri
2026-04-01
Not yet open
Electronic Waveform Lab
Not applicable
80
Kansas, Missouri
2026-04-01
Recruiting
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
MedtronicNeuro
Not applicable
256
Alabama, Arizona, Idaho, Maryland, Missouri, North Carolina, Ohio, Pennsylvania
2026-03-17
Recruiting
IDEAYA Biosciences
Phase 1
155
California, Connecticut, Florida, Georgia, Missouri, New Jersey, New York, Tennessee
2026-03-17
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Massachusetts, Michigan, Minnesota, Missouri
2026-03-16
Recruiting
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Indiana, Massachusetts, Minnesota, Missouri, Nebraska, New York, North Carolina
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
Recruiting
BicycleTx Limited
Phase 2
39
Arizona, Florida, Minnesota, Missouri, New York, Pennsylvania
2026-03-05
Active, closed
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Recruiting
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
Study of DISC-0974-201 in Participants With IBD and Anemia
NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
Disc Medicine, Inc
Phase 2
21
Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas
2026-02-20
Recruiting
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
Hoffmann-La Roche
Phase 2
80
California, Florida, Missouri, New Jersey
2026-02-18
Recruiting
Ambulatory Long Length URodynamics Evaluation
NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
Bright Uro
Not applicable
101
Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington
2026-02-17
Recruiting
Agilis RF TSP Early Feasibility Study
NCT07361445Cardiac Arrythmias, Left Atrial Appendage Closure
Abbott Medical Devices
Not applicable
60
Arkansas, California, Missouri
2026-02-16
Recruiting
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
Zealand Pharma
Phase 3
90
Illinois, Missouri, Nebraska, New York, Pennsylvania, Tennessee
2026-02-11
Recruiting
BioNTech SE
Phase 1
67
Illinois, Maryland, Missouri, New York
2026-02-09
Recruiting
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nebraska
2026-02-06
Recruiting
ImmunAbs Inc.
Phase 1/2
96
Florida, Missouri, Texas
2026-02-05
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Recruiting
Remibrutinib in Real-world Clinical Practice - a US Sub-study
NCT07358780Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
505
Missouri
2026-02-02
Recruiting
Remibrutinib in Real-world Clinical Practice
NCT07358364Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
3,280
Missouri
2026-02-02
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
Arizona, California, Connecticut, Kentucky, Minnesota, Missouri, New Jersey, New York
2026-01-30
Active, closed
MediBeacon
Phase 1
10
Missouri
2026-01-30
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
LTZ Therapeutics, Inc.
Phase 1
42
California, Missouri, New York, Tennessee, Washington
2026-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
Tempus AI
Observational
550
Iowa, Maryland, Missouri, Nevada, New York, North Carolina, North Dakota, Ohio
2026-01-27
Recruiting
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, Ohio
2026-01-20
Recruiting
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Cartesian Therapeutics
Phase 1/2
50
District of Columbia, Missouri, Ohio
2026-01-14
Recruiting
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, New Jersey
2026-01-09
Recruiting
Insmed Gene Therapy LLC
Phase 1
23
Arizona, California, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania, Texas
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1/2
27
Arizona, California, Florida, Illinois, Maryland, Michigan, Missouri, New York
2026-01-09
Recruiting
Biogen
Phase 2
81
California, Colorado, Illinois, Kansas, Michigan, Minnesota, Missouri, Nebraska
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Recruiting
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Tyra Biosciences, Inc
Phase 2
285
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Active, closed
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Missouri, Nebraska, New York
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, New York
2025-12-12
Recruiting
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
BeOne Medicines
Phase 1
186
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Illinois, Missouri, New York, Ohio, Washington
2025-12-09
By invitation
NuvOx LLC
Observational
40
Arizona, Connecticut, Missouri, North Carolina
2025-12-08
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Active, closed
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, California, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
Recruiting
Pfizer
Phase 3
450
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
Pfizer
Phase 1/2
138
Arizona, California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-12-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Recruiting
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Arkansas, California, District of Columbia, Florida, Missouri, New York, Tennessee, Texas
2025-11-26
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Active, closed
AbbVie
Phase 1
142
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Active, closed
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, North Carolina
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
273
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Active, closed
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Active, closed
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Recruiting
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Active, closed
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Recruiting
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
340
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
California, Missouri, Pennsylvania
2025-10-16
Active, closed
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
Active, closed
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Recruiting
Z1 Hip System: Post-Market Clinical Follow Up Study
NCT07104279Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
Zimmer Biomet
Observational
300
Missouri, North Carolina, Ohio, Oregon, Virginia
2025-10-13
Recruiting
Novartis Pharmaceuticals
Phase 2
140
California, District of Columbia, Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas
2025-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 1
126
Florida, Missouri, Texas
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2025-10-08
By invitation
Abyrx, Inc.
Observational
150
Florida, Missouri
2025-10
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
NCT06813820Left Ventricle Remodeling, Left Ventricle Dilated, CHF
BioVentrix
Not applicable
135
Arizona, Florida, Illinois, Missouri, Oklahoma, Pennsylvania
2025-09-29
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Active, closed
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Colorado, Florida, Illinois, Maryland, Missouri, Montana
2025-09-26
Recruiting
Satellos Bioscience, Inc.
Phase 2
30
California, Missouri, Ohio, Tennessee
2025-09-25
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
Terremoto Biosciences Inc.
Phase 1/2
248
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Active, closed
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Active, closed
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Illinois, Missouri
2025-09-18
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
ColoSense Post-Approval Study
NCT07069556Colorectal Cancer (Diagnosis)
Geneoscopy, Inc.
Observational
12,500
Missouri
2025-09-05
Recruiting
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri
2025-09-05
Active, closed
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
By invitation
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
NCT07108114Metastatic Solid Tumors
Solve Therapeutics
Phase 1
70
California, Missouri, Ohio, Pennsylvania, Texas, Washington
2025-08-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Active, closed
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
The DistaSense VITALS Study
NCT07217327Detection of Heart Rate and Respiratory Rate
Life Detection Technologies
Observational
20
Missouri, Ohio
2025-08-13
Active, closed
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
400
Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri, Nevada
2025-08-08
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Active, closed
GlaxoSmithKline
Phase 2
168
Kentucky, Missouri, Nebraska, New York, Pennsylvania, Texas
2025-08-06
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Active, closed
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Windward Bio
Phase 2
600
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Active, closed
Pfizer
Phase 3
151
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Active, closed
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Recruiting
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Active, closed
ViiV Healthcare
Phase 1
107
California, Florida, Illinois, Missouri, New York, Ohio, Pennsylvania, Texas
2025-07-10
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
Imunon
Phase 3
500
Florida, Louisiana, Michigan, Minnesota, Missouri, New York, Oregon, South Dakota
2025-07-09
Recruiting
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Active, closed
Sanofi
Phase 2
105
Alabama, California, Florida, Georgia, Iowa, Massachusetts, Missouri, New York
2025-07-07
Not yet open
Rhaeos, Inc.
Observational
17
Missouri
2025-07
Active, closed
Monte Rosa Therapeutics, Inc
Phase 1
100
Florida, Kansas, Missouri, Texas
2025-06-27
Recruiting
Hoffmann-La Roche
Phase 3
75
California, Florida, Kentucky, Minnesota, Missouri, Virginia
2025-06-27
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
By invitation
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Recruiting
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Recruiting
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Active, closed
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
344
Minnesota, Missouri, Ohio, Utah
2025-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NCT07680244Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
Carl Zeiss Meditec-Dublin CoCe
Not applicable
400
Arizona, California, Florida, Maine, Missouri
2025-05-23
Recruiting
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Delaware, Florida, Maryland, Missouri
2025-05-22
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2025-05-22
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Active, closed
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, District of Columbia, Florida, Georgia, Massachusetts, Minnesota, Missouri, North Carolina
2025-05-14
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Active, closed
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Recruiting
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-05-06
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Active, closed
Hoffmann-La Roche
Observational
44
California, Minnesota, Missouri
2025-04-29
By invitation
Vertex Pharmaceuticals Incorporated
Phase 2
44
Missouri, North Carolina, Virginia
2025-04-28
Recruiting
Stelexis BioSciences
Phase 1
105
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
California, Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, New York
2025-04-28
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Recruiting
Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries
NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma
Checkpoint Surgical Inc.
Not applicable
60
Indiana, Missouri, Ohio, Washington
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Active, closed
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Corcept Therapeutics
Phase 2
270
Alabama, California, Colorado, Florida, Illinois, Minnesota, Missouri, New Mexico
2025-04-11
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
33
California, Florida, Missouri, Ohio, Texas
2025-04-07
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Recruiting
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Missouri
2025-03-31
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Active, closed
Apogee Therapeutics, Inc.
Phase 1
31
California, Illinois, Missouri, Oklahoma, Pennsylvania
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Recruiting
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
Clover Biopharmaceuticals USA, LLC
Phase 1
160
Arizona, Florida, Kentucky, Missouri, Tennessee
2025-03-21
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
NCT06915363Knee Pain Chronic, Knee Osteoarthritis, Cartilage Damage, Cartilage Defects of the Knee
BioPoly LLC
Not applicable
152
California, Indiana, Kentucky, Minnesota, Missouri
2025-03-17
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Recruiting
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Umoja Biopharma
Phase 1
106
California, Illinois, Michigan, Missouri, Nebraska, Ohio, Washington
2025-03-10
Active, closed
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Recruiting
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Recruiting
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Active, closed
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Dogwood Therapeutics Inc.
Phase 2
240
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Missouri
2025-02-21
Active, closed
BioMarin Pharmaceutical
Phase 1
6
California, Missouri, Ohio, South Carolina
2025-02-21
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2025-02-20
Active, closed
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Active, closed
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Active, closed
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Recruiting
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Alabama, Arizona, Arkansas, California, Colorado, Illinois, Missouri, Nevada
2025-02-01
Recruiting
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
Validity of Viome's Oral/throat Cancer Test
NCT06174428Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Viome
Observational
1,000
Missouri, Tennessee
2025-01-27
Recruiting
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
Solventum US LLC
Not applicable
90
Indiana, Missouri, Pennsylvania
2025-01-20
Active, closed
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
BeOne Medicines
Phase 1
695
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
LigaChem Biosciences, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Active, closed
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Active, closed
ViiV Healthcare
Phase 2
229
Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Missouri
2024-12-20
Active, closed
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
ViewFlex X ICE First-in-Human Study
NCT06772493Cardiac Arrhythmias
Abbott Medical Devices
Observational
500
Arkansas, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Texas
2024-12-16
Active, closed
Treeline Biosciences, Inc.
Phase 1
50
California, Missouri, New York, Tennessee
2024-12-16
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Arcturus Therapeutics, Inc.
Phase 2
33
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Missouri
2024-12-12
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Active, closed
Kuros Biosurgery AG
Not applicable
60
California, Michigan, Missouri, Pennsylvania, Tennessee, Washington
2024-12-06
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Active, closed
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Active, closed
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Recruiting
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Recruiting
CoMind Early Feasibility Study
NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage
CoMind Technologies Limited
Observational
581
Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri
2024-11-27
Recruiting
BeOne Medicines
Phase 1/2
80
Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
Amgen
Phase 1
40
California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Recruiting
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Active, closed
Pfizer
Phase 3
636
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Active, closed
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Active, closed
MBX Biosciences
Phase 2
60
Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas
2024-10-31
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Active, closed
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Active, closed
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Active, closed
AstraZeneca
Phase 3
768
Arkansas, California, Florida, Missouri, New York, Ohio, Pennsylvania, Tennessee
2024-10-04
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, New York, Pennsylvania
2024-10-03
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-03
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Active, closed
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Active, closed
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
NCT06564194Respiratory Syncytial Virus (RSV), Infectious Disease
Immorna Biotherapeutics, Inc.
Phase 1
75
Florida, Louisiana, Missouri
2024-09-25
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Active, closed
Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population
NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Cochlear
Not applicable
50
Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania
2024-09-17
Recruiting
GlaxoSmithKline
Phase 3
440
California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah
2024-09-11
Active, closed
Noema Pharma AG
Phase 2
164
Arizona, California, Florida, Georgia, Massachusetts, Michigan, Missouri, Nebraska
2024-09-10
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Active, closed
Eli Lilly and Company
Phase 1
302
California, Florida, Missouri, Texas
2024-09-05
Rows per page Showing 1–500 of 1002
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/missouri

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,002 of those studies with a site in Missouri.

How many clinical trials are recruiting in Missouri?

536 of the 1,002 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 15 have not yet opened recruitment, 406 are active but closed to new participants, and 45 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Missouri), 1,002 studies
PhaseStudiesRecruitingShare
Phase 324312324.3%
Phase 221611121.6%
Phase 11638816.3%
Phase 1/21337813.3%
Not applicable1004810%
Observational99569.9%
Phase 2/331193.1%
Phase 416131.6%
Early Phase 1100.1%

Most active sponsors

Lead sponsors with the most studies (Missouri)
Lead sponsorStudiesRecruiting
AstraZeneca4619
Merck Sharp & Dohme LLC3822
AbbVie2011
Janssen Research & Development, LLC208
Pfizer2010
Eli Lilly and Company197
Hoffmann-La Roche196
GlaxoSmithKline1710
Novartis Pharmaceuticals1611
Amgen136
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.